Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) yesterday and set a price ...

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that ...

Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its ...

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche's Luxturna and Novartis' Zolgensma.

Inc. It is positioned to become a global leader in genetic medicines developed around the AAV vector. AAV is engineered to deliver genetic information that codes for the production of healthy genes to ...

Explore the role and challenges of AAV characterization, the significance of capsid filling, and the best methods to enhance gene therapy.